Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.43 |
| ▸ | PDE4A | P27815 | 4/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTAFR | P25105 | 2/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.37 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10195820 | 0.81 | CHEK1 (0.43) | SYKPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL10196382 | 0.80 | SYK (0.67) | SYKACHEPDE4DPDE4APDE4B | |
| SCHEMBL18481754 | 0.76 | SYK (0.49) | SYKPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12801197 | 0.75 | PDE4D (0.38) | SYKPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12801199 | 0.75 | KMT2A (0.40) | SYKPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL15033946 | 0.73 | PIK3CA (0.49) | SYKPIK3R1PIK3CA | |
| SCHEMBL12448339 | 0.72 | TBK1 (0.43) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1667476 | 0.72 | TBK1 (0.43) | PDE4DPDE4APDE4BPDE4CKMT2A | |
| SCHEMBL13415003 | 0.72 | SYK (0.43) | SYKPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12180595 | 0.71 | PDE4D (0.58) | SYKACHEPDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187478-B2 | Substituted naphthyridines and their use as medicaments | Boehringer Ingellheim International GmbH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | SYK 3856/4885ACHE 1308/4885PDE4D 1389/4885 |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | SYK 3856/4885ACHE 1308/4885PDE4D 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.